Top Markets
Coin of the day
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
Ранг среди акций #32327
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Цена акции
$0.88
Последняя синхронизация: 2026-08-17
Рыночная капитализация
$10.41M
Изменение (1 день)
-7.26%
Изменение (1 год)
-50.56%
Страна
SG
Торговля CytoMed Therapeutics Limited (GDTC)

Категория

Коэффициент P/S для CytoMed Therapeutics Limited (GDTC)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций CytoMed Therapeutics Limited, текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для CytoMed Therapeutics Limited с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
- -
KR